Fenwick represented MRL Ventures Fund, the strategic life sciences investment arm of Merck & Co., Inc. that is focused on innovative therapeutics companies developing transformative medicines, in its participation in Imago BioSciences’ $80 million Series C financing. The round was led by Farallon Capital Management, with participation from new investors including funds and accounts advised by T. Rowe Price Associates, funds and accounts managed by Blackrock Advisors, Surveyor Capital (a Citadel company), Irving Investors and Kingdon Capital Management. In addition to MRL Ventures Fund, existing investors participating in the financing include a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, HighLight Capital, Pharmaron Investments, Greenspring Associates and Xeraya Capital.
Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders targeting epigenetic enzymes. The company will use the proceeds from the financing to complete a Phase 3 study of bomedemstat for the treatment of myeloproliferative neoplasms. More information can be obtained from Imago BioSciences’ announcement.
The Fenwick transaction team included corporate partner Ian Goldstein and associate Andrew Murphy.